Johnson & Johnson - About the company
Johnson & Johnson is a public company based in New Brunswick (United States), founded in 1886 by Edward Mead Johnson and Tyler Rochwerg. It operates as a Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products. Johnson & Johnson has raised an undisclosed amount in funding. The company has 1444 active competitors, including 87 funded and 185 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.
Company Details
Manufacturer, developer, and supplier of beauty care products, medical devices, and pharmaceutical products. The company working in medical devices are 3-D printing artificial joints personalized for each patient, while researchers in pharmaceuticals use AI to discover lifesaving drugs. It also pride on fostering healthy supplier relationships that are built on trust, transparency and unparalleled innovation, quality and reliability with an extended supply base comprising about 50,000 suppliers across our three business segments. In 2022, the company recorded annual revenues of $96.31B and a net profit of $12.72B.
- Website
- www.jnj.com/
- Email ID
- *****@its.jnj.com
- Registered Address
- Higi House, L.B.S. Marg, Mulund West, Mumbai, Mumbai, Mumbai, Maharashtra, India, 400080
Key Metrics
Founded Year
1886
Location
New Brunswick, United States
Stage
Public
Latest Funding Round
Investors
Ranked
6th among 1444 active competitors
Annual Revenue
$1B+ as on Dec 31, 2025
Employee Count
133,830 as on Sep 30, 2026
Investment & Acquisitions
Exit Details
Public
Legal entities associated with Johnson & Johnson
Johnson & Johnson is associated with 12 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
W & J Partner s. r. o. CIN: 47666455 , Czech Republic, Active | Dec 17, 1992 | - | - | |
J&J marketing business s.r.o. CIN: 29450969 , Czech Republic, Active | Sep 05, 2012 | - | - | |
Pharma Vision Technology s.r.o. CIN: 29396638 , Czech Republic, Active | Feb 09, 2012 | - | - | |
J&J Provider s.r.o. CIN: 17721296 , Czech Republic, Active | Nov 09, 2022 | - | - | |
Health 4 Beauty s.r.o. CIN: 17126215 , Czech Republic, Active | May 10, 2022 | - | - | |
H+A+D Marketing Corporation s. r. o. CIN: 08217602 , Czech Republic, Active | May 30, 2019 | - | - | |
JJ SUPPORT s.r.o. CIN: 06711570 , Czech Republic, Active | Dec 22, 2017 | - | - | |
J&J XXX LTD CIN: 13342325 , United Kingdom, Active | Apr 18, 2021 | £0 - £1M (As on Apr 30, 2023) | - | |
JOHNSON & JOHNSON SERVICES, INC. CIN: 3591138 , United States, Active | Nov 13, 2002 | $1B+ (As on Dec 31, 2023) | - | - |
JOHNSON & JOHNSON SURGICAL VISION INDIA PRIVATE LIMITED CIN: U24231KA2004PTC034235 , India, Active | Jun 29, 2004 | ₹500 - ₹1,000 Cr (As on Mar 31, 2025) | 214 (As on Oct 31, 2024) | |
JOHNSON & JOHNSON CIN: 200406 , United States, Active | $1B+ (As on Dec 31, 2025) | 131900 (As on Dec 31, 2023) | - | |
JOHNSON & JOHNSON PRIVATE LIMITED CIN: U33110MH1957PTC010928 , India, Active | Sep 05, 1957 | ₹1,000+ Cr (As on Mar 31, 2025) | 1837 (As on Feb 01, 2026) |
Johnson & Johnson's IPO details
Johnson & Johnson got listed on Jan 06, 1978.
Click here to take a look at Johnson & Johnson's IPO in detail
Sign up to download Johnson & Johnson's company profile
Johnson & Johnson's funding and investors
Johnson & Johnson has raised funding over 4 rounds. Its first funding round was on Aug 02, 2011. Johnson & Johnson has 18 institutional investors.
Here is the list of recent funding rounds of Johnson & Johnson:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 20, 2025 | 9667247 | Conventional Debt | 8526974 | 1961255 | 6147330 | 3350802 |
May 01, 2023 | 7903657 | Grant (prize money) | 8828463 | 7474572 | 2247626 | |
Nov 05, 2018 | 4206424 | Post IPO | 7447026 | 4660149 | 5812666 |
View details of Johnson & Johnson's funding rounds and investors
Johnson & Johnson's founders and board of directors
Founder? Claim ProfileThe founders of Johnson & Johnson are Edward Mead Johnson and Tyler Rochwerg. Joaquin Duato is the CEO of Johnson & Johnson.
Here are the details of Johnson & Johnson's key team members:
- Edward Mead Johnson: Former Co-Founder of Johnson & Johnson and founder of 1 other company. Contact Info: 1 email address
- Tyler Rochwerg: Former Co-Founder of Johnson & Johnson.
- Joaquin Duato: CEO of Johnson & Johnson. Contact Info: 3 email addresses
View details of Johnson & Johnson's Founder profiles and Board Members
Johnson & Johnson's employee count trend
Johnson & Johnson has 133,830 employees as of Sep 26. Here is Johnson & Johnson's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Johnson & Johnson's Competitors and alternates
Top competitors of Johnson & Johnson include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Johnson & Johnson, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 83/100 | |
2nd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 81/100 | |
3rd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 79/100 | |
4th | AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 76/100 | |
5th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 75/100 | |
6th | Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 76/100 | |
7th | Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 71/100 | |
8th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 71/100 | |
9th | Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 70/100 | |
10th | Genentech 1976, San Francisco (United States), Acquired | R&D company focused on manufacturing drugs for multiple therapeutic areas | $72.5M | 68/100 |
Looking for more details on Johnson & Johnson's competitors? Click here to see the top ones
Johnson & Johnson's Investments and acquisitions
Johnson & Johnson has made 38 investments in companies including Tempo Therapeutics and SonoThera. Johnson & Johnson has also acquired 59 companies including Firefly Bio and Atraverse Medical.Here is the list of investments & acquisitions:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Sep 18, 2026 | Investments | 2014 | San Diego (United States) | |
Jun 08, 2026 | Investments | 2022 | San Francisco (United States) | |
Jun 08, 2026 | Acquisition | 2022 | San Francisco (United States) |
See all investments and acquisitions by Johnson & Johnson
Reports related to Johnson & Johnson
Here is the latest report on Johnson & Johnson's sector:
News related to Johnson & Johnson
Media has covered Johnson & Johnson for a total of 398 events in the last 1 year, 244 of them have been about company updates and 13 about partnerships.
•
Johnson & Johnson Announces Sustained Efficacy of TREMFYA® in Crohn's Disease Over Three YearsPR Newswire•Oct 13, 2026•Johnson & Johnson
•
Johnson & Johnson: New Icotyde Data Show Robust 2-Year Results in Plaque Psoriasis TreatmentPR Newswire•Oct 09, 2026•Johnson & Johnson
•
Dawson returns to CJFHC as CEO after tenure at Johnson & JohnsonBee Star•Oct 09, 2026•Johnson & Johnson
•
Breast Cancer Awareness Month Raises Questions About Antipsychotic Drug WarningsPR Newswire•Oct 07, 2026•Lilly, Wisner Baum, Johnson & Johnson
•
Johnson & Johnson Presents Contact Lens Research Highlighting Moisture Retention DifferencesEyewire News•Sep 29, 2026•Johnson & Johnson
•
J&J and Legend Biotech's Carvykti Shows Long-Term Survival Benefits in Multiple Myeloma TrialBioSpace•Sep 25, 2026•Legend Biotechnology, Johnson & Johnson
•
•
J&J's Caplyta Shows Positive Results in Bipolar I Disorder Trialhttps://www.clinicaltrialsarena.com/•Sep 22, 2026•Johnson & Johnson
•
European Commission approves Johnson & Johnson's ICOTYDE™ (icotrokinra) for plaque psoriasisGlobeNewswire•Sep 21, 2026•Johnson & Johnson
•
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive DisorderBusiness Wire•Sep 15, 2026•Contineum Therapeutics, Johnson & Johnson
Are you a Founder ?
FAQs about Johnson & Johnson
Explore our recently published companies
- Spire Blockchain - Sugar Land based, 2021 founded, Unfunded company
- Supra - Unfunded company
- Human Data Income - United Kingdom based, 2017 founded, Unfunded company
- Superflash - Unfunded company
- Swapter - Kyiv based, 2022 founded, Unfunded company
- SvetRating - Palo Alto based, 2018 founded, Unfunded company
